Sign up for a new account.
And get access to
The latest T1D content
Research that matters
Our daily questions
Sign up by entering your info below.
Reset Your Password
We will email you instructions to reset your
Lilly and Dexcom team up on new program to help improve diabetes management
Eli Lilly and Company (NYSE: LLY) and DexCom, Inc. (NASDAQ: DXCM) announced today a joint program for U.S. healthcare providers (HCPs) about Lilly’s new rapid-acting mealtime insulin Lyumjev™ (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), now available in U.S. pharmacies, and Dexcom G6 CGM Systems. The program is designed to help clinicians use data to inform diabetes management, including giving visibility to the benefits of a new mealtime insulin.
HCPs treating type 1 and type 2 diabetes will be able to assess their patients’ glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro, either in blinded or unblinded mode, helping them quickly identify adult patients who struggle to manage their postprandial glucose (PPG) levels (glucose levels following meals) and who may benefit from a treatment like Lyumjev. As PPG is often overlooked as a significant contributor to A1C,1 this partnership also aims to elevate PPG monitoring as an important component of diabetes treatment management.
“When it comes to treating diabetes, our partnership with Dexcom has the potential to be meaningful for HCPs who want to help their patients who may be struggling to manage their blood glucose levels after meals,” said Adrienne Brown, vice president, U.S. Diabetes and Connected Care, Lilly. “Through this program, we can inspire confidence as clinicians and their patients evaluate new treatment options by showcasing how using these resources together can inform diabetes care.”
Lilly and Dexcom will enhance HCP education by jointly sharing information about Lyumjev and the Dexcom G6 and G6 Pro through a variety of channels.
“We are thrilled to partner once again with a leader in diabetes care like Lilly,” said Rick Doubleday, chief commercial officer at Dexcom. “Our goal is that the real-time data provided through Dexcom G6 and Dexcom G6 Pro will allow healthcare providers to help their patients with diabetes make more informed decisions, measure and evaluate their time in range, and have more visibility to the potential benefits of transitioning to a new mealtime insulin such as Lyumjev.”
Click here to read the full press release
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Join our mailing list for more about T1D